Johnson & Johnson · JNJ · Next earnings

Johnson & Johnson reports Wednesday, Jan 20, 2027

JNJ reports before market open with consensus EPS at — and revenue at —. Last quarter: J&J raises outlook as oncology leads, while MedTech lags

Reports Before market open76 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $2.90 Analyst average (12 estimates)
Consensus revenue $26.41B Analyst average (10 estimates)
Report date Jan 20, 2027 Wednesday, date estimated
Session Before market open 76 days away

Where JNJ left off: FY2026 Q3

Full report

J&J raises outlook as oncology leads, while MedTech lags

EPS surprise +2.8% Reported $2.59 vs $2.52
Revenue surprise +0.1% Reported $25.40B vs $25.38B
Stock move -5.7% Event window
Subsequent drift 0.0% Up to 20 sessions

Management raised 2026 operational sales-growth guidance to 6.7%–7.1% and upgraded its EPS outlook.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • The $5.5 billion talc litigation settlement creates a significant GAAP impact.
  • Firefly Bio integration and the Cell BioMedicines collaboration may add expenses and IPR&D dilution.
  • Biosimilar competition, including pressure on STELARA, remains a risk.
  • Pricing pressure outside the United States and currency fluctuations could weigh on results.
  • Geopolitical disruption in the Middle East may affect MedTech ordering and procurement.

Questions analysts left open

  • Whether future growth will rely more on internal investment or acquisitions.
  • How management plans to improve MedTech performance, particularly outside the United States.
  • The uptake and market potential of ICOTYDE in psoriasis and inflammatory bowel disease.
  • The revenue and guidance effects of acquired-process research and development from Firefly Bio and Cell BioMedicines.
  • The timing and scale of upcoming data readouts and regulatory approvals.

Ask FN2 about JNJ next report

Transcript, numbers and history already loaded
What should I watch for in JNJ's next earnings report?How did JNJ guide last quarter, and is consensus above or below that?Give me the bull and bear case going into JNJ earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the JNJ recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent JNJ quarters

All JNJ earnings
-5.7%FY2026 Q3-2.7%FY2026 Q2+0.9%FY2026 Q1-0.1%FY2025 Q4

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.